Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317901 | 0.90 | MAP2K1 (0.58) | MAP2K1MAP2K2 | |
| SCHEMBL15088120 | 0.87 | MAP2K1 (0.45) | MAP2K1MAP2K2 | |
| SCHEMBL6323301 | 0.83 | MAP2K1 (0.64) | MAP2K1MAP2K2 | |
| SCHEMBL6318708 | 0.79 | MAP2K1 (0.61) | MAP2K1MAP2K2 | |
| SCHEMBL3973399 | 0.76 | MAP2K1 (0.48) | MAP2K1MAP2K2 | |
| SCHEMBL1488337 | 0.75 | MAP2K1 (0.53) | MAP2K1MAP2K2 | |
| SCHEMBL1488520 | 0.75 | MAP2K1 (0.59) | MAP2K1MAP2K2 | |
| SCHEMBL4234407 | 0.74 | MAP2K2 (1.00) | MAP2K1MAP2K2 | |
| SCHEMBL29781352 | 0.73 | MAP2K1 (0.65) | MAP2K1MAP2K2 | |
| SCHEMBL2021798 | 0.72 | MAP2K1 (0.62) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050049276-A1 | Imidazopyridines and triazolopyridines | WARNER-LAMBERT COMPANY, LLC | 2005-03-03 | — | — | US | claimed |
| US-20050049276-A1 | Imidazopyridines and triazolopyridines | WARNER-LAMBERT COMPANY, LLC | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049276-A1 | Imidazopyridines and triazolopyridines | QDPR, DPYD, CYP3A5 | MAP2K1 2549/4885MAP2K2 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.